These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21340042)

  • 21. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage.
    Di Marco F; Braido F; Santus P; Scichilone N; Blasi F
    Eur Rev Med Pharmacol Sci; 2014; 18(3):321-32. PubMed ID: 24563430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of cefditoren against a special collection of clinical isolates of Streptococcus pneumoniae from Hungary.
    Nagy E; Marton A; Hajdú E
    Acta Microbiol Immunol Hung; 2003; 50(2-3):119-24. PubMed ID: 12894483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefditoren: a clinical overview.
    Giuliano S; Acquasanta A; Martini L; Sbrana F; Flammini S; Tascini C
    New Microbiol; 2023 Feb; 46(1):9-17. PubMed ID: 36853812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
    Critchley IA; Brown SD; Traczewski MM; Tillotson GS; Janjic N
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4382-9. PubMed ID: 17908940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE; Brown S; Felmingham D
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections. Part II].
    Shimada J; Ishihara R; Suzuki Y; Ishii Y; Nakazawa A; Deguchi K
    Jpn J Antibiot; 1997 Sep; 50(9):756-67. PubMed ID: 9394236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.
    Giménez MJ; Aguilar L; Granizo JJ
    Multidiscip Respir Med; 2018; 13():40. PubMed ID: 30410757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study.
    van Zyl L; le Roux JG; LaFata JA; Volk RS; Palo WA; Flamm R; Hom RC
    Clin Ther; 2002 Nov; 24(11):1840-53. PubMed ID: 12501878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).
    Sader HS; Fritsche TR; Mutnick AH; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):515-25. PubMed ID: 14596971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries.
    Lee MY; Ko KS; Oh WS; Park S; Lee JY; Baek JY; Suh JY; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A clinical study on cefditoren pivoxil granules in the pediatric field].
    Mori A; Meguro H; Terashima I; Fujii R
    Jpn J Antibiot; 1993 Jul; 46(7):577-88. PubMed ID: 8371493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.